Solid organ transplant (SOT) recipients are at risk of complications from COVID‐19. Nirmatrelvir/ritonavir (Paxlovid) can reduce mortality from COVID‐19 but is contraindicated in patients receiving calcineurin inhibitors (CI), which depend… Click to show full abstract
Solid organ transplant (SOT) recipients are at risk of complications from COVID‐19. Nirmatrelvir/ritonavir (Paxlovid) can reduce mortality from COVID‐19 but is contraindicated in patients receiving calcineurin inhibitors (CI), which depend on cytochrome p4503A (CY3PA). In this study, we aim to show the feasibility of nirmatrelvir/ritonavir administration to SOT recipients receiving CI with coordination of medication management and limited tacrolimus trough monitoring.
Keywords:
lives nirmatrelvir;
one transplant;
nirmatrelvir ritonavir;
ritonavir one;
saving lives;
transplant
Journal Title: Transplant Infectious Disease
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transplant Infectious Disease
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!